OBJECTIVE: To improve the compliance with subcutaneous specific immunotherapy (SCIT) by analyzing the causes of stopping SCIT in asthmatic children. METHODS: A telephone follow-up was conducted in the asthmatic children who received SCIT but did not finished the 3-year course of treatment from June 2005 to October 2010, so as to analyze the causes of stopping SCIT. RESULTS: A total of 616 asthmatic children received SCIT, and 322 (52.2%) of them stopped SCIT.A total of 127 cases (39.4%) of the 322 children received telephone follow-up. In the 127 children, 53 (41.8%) stopped the SCIT for the reason of bad effecacy, 29 (22.8%) for remission of asthma,12 (9.4%) for expensive fees, 10 (7.9%) for complex process of treatment, 10 (7.9%) for adverse reaction, 9 (7.1%) for long distance from the hospital, and 4 (3.1%) for having no time for treatment. And 69 (54.3%) of them stopped SCIT in the first year, 28 (22.1%) in the second year, and 30 (23.6%) in the third year. Currently, 85 cases (66.9%) of the 127 asthmatic children were up to the control level, and the other 42 cases were not. There was significant difference in the control level of asthma berween the group receiving treatment with regular inhaled corticosteroids (ICS) and the group receiving treatment with irregular ICS (P<0.01). CONCLUSIONS: Bad efficacy, remission of asthma, expensive fees, complex process of treatment, and adverse reaction are the main reasons contributing to the stop of SCIT in asthmatic children. To improve the compliance with SCIT, It is important to make the patients and their parents understand the long treatment course and slow effect of SCIT, encourage them to use objective indices for evaluating the state of asthma, and effectively prevent and treat the adverse reactions.
Key words
Asthma /
Subcutaneous specific immunotherapy /
Compliance /
Adverse reaction /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1]Incorvaia C, Frati F. One century of allergen-specific immunotherapy for respiratory allergy[J]. Immunotherapy, 2011, 3(5): 629-635.
[2]Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary[J]. Eur Respir J, 2008, 31(1): 143-178.
[3]中华医学会儿科学分会呼吸学组.儿童支气管哮喘诊断与防治指南(2008年修订)[J].中华儿科杂志,2008,46(10):745-753.
[4]王模奎,黄英,刘恩梅,戴继宏,陈坤华,蒋永惠,等.标准化屋尘螨变应原制剂治疗儿童变应性哮喘68例[J].中国新药与临床杂志,2006,25(12):935-938.
[5]冯辉,向莉,申昆玲.屋尘螨皮下特异性免疫治疗的哮喘患儿肺功能及免疫学动态变化[J].中国当代儿科杂志,2010,12(9):715-719.
[6]彭万胜,闫会丽,陈信,杨锡强,刘恩梅.螨变应原舌下特异性免疫治疗螨致敏哮喘患儿的Meta分析[J].中华儿科杂志,2007,45(10):736-741.
[7]Webber CM, Calabria CW. Assessing the safety of subcutaneous immunotherapy dose adjustments[J]. Ann Allergy Asthma Immunol, 2010, 105(5): 369-375.
[8]魏金凤,彭万胜,刘恩梅.哮喘患儿屋尘螨特异性免疫治疗的疗效及依从性分析[J].中国药学与临床杂志,2011,30(5):459-461.
[9]陈芸,黄英,王模奎,陈坤华,蒋永惠.标准化屋尘螨变应原制剂治疗195例儿童哮喘安全性的初步评价[J].中国新药与临床杂志.2010,29(4):292-295.
[10]桂晓钟,陈涌,赵军,程静.变应性鼻炎皮下注射和舌下含服特异性免疫治疗依从性对比[J].中国耳鼻咽喉头颈外科,2010,17(12):631-633.
[11]Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three yeas of specific immunotherapy may be sufficient in house dust mite respiratory allergy[J].J Allergy Clin Immunol, 2011, 127(1): 57-63.
[12]沈华浩,应英华.新版全球哮喘防治创议(GINA)方案的评价和解读[J].临床内科杂志,2007,24(4):221-224.
[13]金婷婷,张晓波,张明智,张皓,任慈芳,冯海燕,等.哮喘儿童尘螨特异性免疫治疗的全身不良反应[J].临床儿科杂志,2010,28(5):459-461.
[14]Cools M, Van Bever HP, Weylev JJ, Steven WJ. Long-term effect of specific immunotherapy, administered during childhood, in asthmatic patiants allergic to either house-dust mite or to both house-dust mite and grass pollen[J]. Allergy, 2000, 55(1): 69-73.